229 related articles for article (PubMed ID: 15994369)
21. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
22. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles.
Ortner A; Wernig K; Kaisler R; Edetsberger M; Hajos F; Köhler G; Mosgoeller W; Zimmer A
J Drug Target; 2010 Jul; 18(6):457-67. PubMed ID: 20050817
[TBL] [Abstract][Full Text] [Related]
23. Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide.
Rorstad OP; Wanke I; Coy DH; Fournier A; Huang M
Mol Pharmacol; 1990 Jun; 37(6):971-7. PubMed ID: 2163020
[TBL] [Abstract][Full Text] [Related]
24. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
25. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.
Ramos-Álvarez I; Mantey SA; Nakamura T; Nuche-Berenguer B; Moreno P; Moody TW; Maderdrut JL; Coy DH; Jensen RT
Peptides; 2015 Apr; 66():26-42. PubMed ID: 25698233
[TBL] [Abstract][Full Text] [Related]
26. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P
Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009
[TBL] [Abstract][Full Text] [Related]
27. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
Couvineau A; Rouyer-Fessard C; Laburthe M
Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910
[TBL] [Abstract][Full Text] [Related]
28. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
[TBL] [Abstract][Full Text] [Related]
29. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2).
Langer I; Gaspard N; Robberecht P
Br J Pharmacol; 2006 Aug; 148(8):1051-9. PubMed ID: 16783404
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
32. Novel extended and branched N-terminal analogs of VIP.
Dangoor D; Rubinraut S; Fridkin M; Gozes I
Regul Pept; 2006 Nov; 137(1-2):42-9. PubMed ID: 16962672
[TBL] [Abstract][Full Text] [Related]
33. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
34. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
35. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Dickson L; Aramori I; McCulloch J; Sharkey J; Finlayson K
Neuropharmacology; 2006 Nov; 51(6):1086-98. PubMed ID: 16930633
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of VIP-induced neuroprotection against neonatal excitotoxicity.
Rangon CM; Dicou E; Goursaud S; Mounien L; Jégou S; Janet T; Muller JM; Lelièvre V; Gressens P
Ann N Y Acad Sci; 2006 Jul; 1070():512-7. PubMed ID: 16888217
[TBL] [Abstract][Full Text] [Related]
37. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
38. Paradoxical antagonism of PACAP receptor signaling by VIP in Xenopus oocytes via the type-C natriuretic peptide receptor.
Lelièvre V; Hu Z; Ioffe Y; Byun JY; Flores A; Seksenyan A; Waschek JA
Cell Signal; 2006 Nov; 18(11):2013-21. PubMed ID: 16723209
[TBL] [Abstract][Full Text] [Related]
39. PACAP and VIP prevent apoptosis in schwannoma cells.
Castorina A; Tiralongo A; Giunta S; Carnazza ML; Rasi G; D'Agata V
Brain Res; 2008 Nov; 1241():29-35. PubMed ID: 18835258
[TBL] [Abstract][Full Text] [Related]
40. Molecular cloning and functional expression of a VIP-specific receptor.
Zhou H; Huang J; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G728-34. PubMed ID: 16959956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]